Literature DB >> 16311342

FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma.

J Settakorn1, N Kaewpila, G F Burns, A S-Y Leong.   

Abstract

AIM: To identify surrogate prognostic markers in intrahepatic cholangiocarcinoma (IHCC).
METHODS: Thirty one cases of IHCC were graded and immunostained for FAT, Ki67, E-cadherin, beta catenin, and HER 2/neu.
RESULTS: Twenty two cases were high grade and 27 had high Ki67 counts. Strong membranous staining of HER 2/neu was found in 10 tumours and reduced membranous E-cadherin and beta catenin in 19 and 18 tumours, respectively. Nuclear localisation of beta catenin was identified in five tumours and 22 showed weak cytoplasmic staining of FAT. Strong HER 2/neu and weak FAT immuno-expression were significantly correlated with high histological grade (p=0.01) and high Ki67 index (p=0.03). Upregulation of HER 2/neu was also significantly associated with nuclear localisation of beta catenin (p=0.01). Reduced membranous beta catenin was significantly related to reduced membranous E-cadherin (p=0.03), weak staining for FAT (p=0.01), and nuclear translocation of beta catenin (p=0.04).
CONCLUSIONS: Reduced immuno-expression of E-cadherin and FAT at their normal membranous location may be potential prognostic markers, and the overexpression of HER 2/neu and beta catenin nuclear translocation may have a role in cholangiocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311342      PMCID: PMC1770788          DOI: 10.1136/jcp.2005.026575

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan.

Authors:  H Suzuki; S Isaji; C Pairojkul; T Uttaravichien
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

2.  Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma.

Authors:  K Sugimachi; K Taguchi; S Aishima; S Tanaka; M Shimada; K Kajiyama; K Sugimachi; M Tsuneyoshi
Journal:  Mod Pathol       Date:  2001-09       Impact factor: 7.842

3.  The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of 'scirrhous-type' and 'nonscirrhous-type' growth.

Authors:  K Kajiyama; T Maeda; K Takenaka; K Sugimachi; M Tsuneyoshi
Journal:  Am J Surg Pathol       Date:  1999-08       Impact factor: 6.394

4.  Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma.

Authors:  Y Ito; T Takeda; Y Sasaki; M Sakon; T Yamada; S Ishiguro; S Imaoka; M Tsujimoto; S Higashiyama; M Monden; N Matsuura
Journal:  Pathol Res Pract       Date:  2001       Impact factor: 3.250

Review 5.  Human cancer syndromes: clues to the origin and nature of cancer.

Authors:  E R Fearon
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

6.  Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry.

Authors:  Yoko Ukita; Masako Kato; Tadashi Terada
Journal:  J Hepatol       Date:  2002-06       Impact factor: 25.083

7.  Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study.

Authors:  K Ashida; T Terada; Y Kitamura; N Kaibara
Journal:  Hepatology       Date:  1998-04       Impact factor: 17.425

8.  Mutation and altered expression of beta-catenin during gallbladder carcinogenesis.

Authors:  Hee Jin Chang; Chang Do Jee; Woo Ho Kim
Journal:  Am J Surg Pathol       Date:  2002-06       Impact factor: 6.394

9.  c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.

Authors:  S-I Aishima; K-I Taguchi; K Sugimachi; M Shimada; K Sugimachi; M Tsuneyoshi
Journal:  Histopathology       Date:  2002-03       Impact factor: 5.087

Review 10.  The cadherin superfamily: diversity in form and function.

Authors:  B D Angst; C Marcozzi; A I Magee
Journal:  J Cell Sci       Date:  2001-02       Impact factor: 5.285

View more
  23 in total

1.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

Review 2.  Molecular profiling of biliary tract cancer: a target rich disease.

Authors:  Apurva Jain; Milind Javle
Journal:  J Gastrointest Oncol       Date:  2016-10

3.  High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K.

Authors:  Warapen Treekitkarnmongkol; Tuangporn Suthiphongchai
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

Review 4.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

5.  Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.

Authors:  Ning Ding; Li Che; Xiao-Lei Li; Yan Liu; Li-Jie Jiang; Biao Fan; Jun-Yan Tao; Xin Chen; Jia-Fu Ji
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

6.  Zonula occludens-1, occludin, and E-cadherin protein expression in biliary tract cancers.

Authors:  Zsuzsanna Németh; Attila Marcell Szász; Aron Somorácz; Péter Tátrai; Júlia Németh; Hajnalka Gyorffy; Attila Szíjártó; Péter Kupcsulik; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

7.  Immunohistochemical Examination of a Resected Advanced Hilar Cholangiocarcinoma Arising in a 29-Year-Old Male without Primary Sclerosing Cholangitis.

Authors:  Taketoshi Suehiro; Takashi Matsumata; Tomohiro Iguchi; Kensaku Sanefuji; Ken-Ichi Nomoto; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  Case Rep Gastroenterol       Date:  2010-05-12

Review 8.  AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.

Authors:  K J Schmitz; H Lang; J Wohlschlaeger; G C Sotiropoulos; H Reis; K W Schmid; H A Baba
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 9.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 10.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.